ES2627154T3 - Métodos de seguimiento y análisis de perfiles de actividad metabólica, usos diagnósticos y terapéuticos de los mismos - Google Patents

Métodos de seguimiento y análisis de perfiles de actividad metabólica, usos diagnósticos y terapéuticos de los mismos Download PDF

Info

Publication number
ES2627154T3
ES2627154T3 ES12721945.9T ES12721945T ES2627154T3 ES 2627154 T3 ES2627154 T3 ES 2627154T3 ES 12721945 T ES12721945 T ES 12721945T ES 2627154 T3 ES2627154 T3 ES 2627154T3
Authority
ES
Spain
Prior art keywords
cell
acidification
cells
volatile
metabolic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12721945.9T
Other languages
English (en)
Spanish (es)
Inventor
Reuven Tirosh
Fernando Patolsky
Hagit PERETZ-SOROKA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd filed Critical Ramot at Tel Aviv University Ltd
Application granted granted Critical
Publication of ES2627154T3 publication Critical patent/ES2627154T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Oncology (AREA)
  • Ecology (AREA)
ES12721945.9T 2011-04-06 2012-04-04 Métodos de seguimiento y análisis de perfiles de actividad metabólica, usos diagnósticos y terapéuticos de los mismos Active ES2627154T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161472213P 2011-04-06 2011-04-06
US201161472213P 2011-04-06
PCT/IL2012/050125 WO2012137207A1 (en) 2011-04-06 2012-04-04 Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same

Publications (1)

Publication Number Publication Date
ES2627154T3 true ES2627154T3 (es) 2017-07-26

Family

ID=46124593

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12721945.9T Active ES2627154T3 (es) 2011-04-06 2012-04-04 Métodos de seguimiento y análisis de perfiles de actividad metabólica, usos diagnósticos y terapéuticos de los mismos

Country Status (11)

Country Link
US (3) US8728758B2 (https=)
EP (1) EP2694962B1 (https=)
JP (1) JP5990254B2 (https=)
KR (1) KR102010600B1 (https=)
CN (1) CN103518133B (https=)
AU (1) AU2012240953B2 (https=)
BR (1) BR112013025782B1 (https=)
CA (1) CA2832031C (https=)
DK (1) DK2694962T3 (https=)
ES (1) ES2627154T3 (https=)
WO (1) WO2012137207A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2832031C (en) 2011-04-06 2019-09-17 Ramot At Tel-Aviv University Ltd. Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same
WO2015057713A1 (en) * 2013-10-14 2015-04-23 Case Western Reserve University Metabolic analyzer for optimizing health and weight management
CN106164286A (zh) 2013-10-22 2016-11-23 拉莫特特拉维夫大学有限公司 用于检测的方法和系统
ITRM20130700A1 (it) * 2013-12-19 2015-06-20 Stichting Katholieke Univ Metodo per il rilevamento di cellule tumorali circolanti
CN105303035A (zh) * 2015-09-29 2016-02-03 上海新窝信息科技有限公司 一种健康监测方法及系统
CA3007606A1 (en) 2015-12-09 2017-06-15 Ramot At Tel-Aviv University Ltd. Method and system for sensing
JP2019526794A (ja) 2016-08-22 2019-09-19 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッドＲａｍｏｔ Ａｔ Ｔｅｌ Ａｖｉｖ Ｕｎｉｖｅｒｓｉｔｙ Ｌｔｄ． 生物検体の検出のための方法およびシステム
KR20190038660A (ko) 2016-08-22 2019-04-08 라모트 앳 텔-아비브 유니버시티 리미티드 피하 센싱을 위한 방법 및 시스템
US11619634B2 (en) * 2017-08-21 2023-04-04 Savicell Diagnostic Ltd. Methods of diagnosing and treating lung cancer
CN110491511B (zh) * 2019-07-24 2023-04-07 广州知汇云科技有限公司 一种基于围术期危险预警的多模型互补增强机器学习方法
IT202000016429A1 (it) * 2020-07-07 2022-01-07 Univ Degli Studi Udine Metodo per la valutazione dell’attivita’ metabolica di una cellula non-tumorale
WO2022109732A1 (en) * 2020-11-26 2022-06-02 12535441 Canada Ltd. Spectral diagnostic system
US20240358835A1 (en) * 2021-08-17 2024-10-31 Orgenesis Inc. Tumor infiltrating lymphocytes with increased metabolic activity

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US7713733B2 (en) * 2001-08-06 2010-05-11 Vanderbilt University Device and methods for detecting the response of a plurality of cells to at least one analyte of interest
JP4625946B2 (ja) * 2004-11-02 2011-02-02 国立大学法人 岡山大学 ｐＨ測定装置及びｐＨ測定方法
EP1736780A1 (en) 2005-06-24 2006-12-27 Eppendorf Array Technologies S.A. Method and means for detecting and/or quantifying hierarchical molecular change of a cell in response to an external stimulus
WO2008018905A2 (en) * 2006-01-17 2008-02-14 Cellumen, Inc. Method for predicting biological systems responses
CA2641954C (en) 2006-03-06 2016-04-26 Zetiq Technologies Ltd. Methods and compositions for identifying a cell phenotype
WO2011000572A1 (de) 2009-07-02 2011-01-06 Patenthandel Portfoliofonds I Gmbh & Co. Kg Verfahren und vorrichtung zum nachweis von biologischen langzeiteffekten in zellen
WO2011031803A1 (en) * 2009-09-08 2011-03-17 Nodality, Inc. Analysis of cell networks
CA2832031C (en) 2011-04-06 2019-09-17 Ramot At Tel-Aviv University Ltd. Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same

Also Published As

Publication number Publication date
US8728758B2 (en) 2014-05-20
US20180038849A1 (en) 2018-02-08
AU2012240953A1 (en) 2013-10-17
WO2012137207A1 (en) 2012-10-11
CA2832031A1 (en) 2012-10-11
KR20140024871A (ko) 2014-03-03
US20130224789A1 (en) 2013-08-29
AU2012240953B2 (en) 2017-02-23
CA2832031C (en) 2019-09-17
DK2694962T3 (en) 2017-06-12
KR102010600B1 (ko) 2019-08-13
CN103518133B (zh) 2016-08-17
JP2014512006A (ja) 2014-05-19
US9784731B2 (en) 2017-10-10
CN103518133A (zh) 2014-01-15
BR112013025782B1 (pt) 2022-09-06
EP2694962A1 (en) 2014-02-12
JP5990254B2 (ja) 2016-09-07
BR112013025782A2 (pt) 2016-12-20
US20140255972A1 (en) 2014-09-11
EP2694962B1 (en) 2017-03-01

Similar Documents

Publication Publication Date Title
ES2627154T3 (es) Métodos de seguimiento y análisis de perfiles de actividad metabólica, usos diagnósticos y terapéuticos de los mismos
Klimmeck et al. Proteomic cornerstones of hematopoietic stem cell differentiation: distinct signatures of multipotent progenitors and myeloid committed cells
Wang et al. Inflammatory markers and development of symptom burden in patients with multiple myeloma during autologous stem cell transplantation
Skayneh et al. EAPB0503, an imidazoquinoxaline derivative modulates SENP3/ARF mediated SUMOylation, and induces NPM1c degradation in NPM1 mutant AML
Erlichman et al. Tumor cell-autonomous pro-metastatic activities of PD-L1 in human breast cancer are mediated by PD-L1-S283 and chemokine axes
Foratori-Junior et al. Is there a difference in the proteomic profile of stimulated and unstimulated saliva samples from pregnant women with/without obesity and periodontitis?
Bauvois et al. Relation of neutrophil gelatinase-associated lipocalin overexpression to the resistance to apoptosis of tumor B cells in chronic lymphocytic leukemia
Rojas et al. Pathological response and immune biomarker assessment in non-small-cell lung carcinoma receiving neoadjuvant immune checkpoint inhibitors
Brignole et al. Bone marrow environment in metastatic neuroblastoma
Brenner et al. CDC25 Inhibition in Acute Myeloid Leukemia–A Study of Patient Heterogeneity and the Effects of Different Inhibitors
Bintintan et al. Predictive factors of immunotherapy in gastric cancer: A 2024 update
Skurikhin et al. Analysis of circulating tumor and cancer stem cells provides new opportunities in diagnosis and treatment of small cell lung cancer
Silvestris et al. Fertility preservation in the era of immuno-oncology: lights and shadows
Kotogány et al. Imidazo [1, 2-b] pyrazole-7-carboxamide derivative induces differentiation-coupled apoptosis of immature myeloid cells such as acute myeloid leukemia and myeloid-derived suppressor cells
Ren et al. Identification of biomarkers affecting cryopreservation recovery ratio in ram spermatozoa using tandem mass tags (TMT)-based quantitative proteomics approach
Aasebø et al. Proteomic profiling of primary human acute myeloid leukemia cells does not reflect their constitutive release of soluble mediators
Saitta et al. Evaluation of semen self-sampling yield predictors and CTC isolation by multi-color flow cytometry for liquid biopsy of localized prostate cancer
Cruz et al. Nucleolin as a potential biomarker for canine malignant neoplasia
Thylur Puttalingaiah et al. Excess Potassium Promotes Autophagy to Maintain the Immunosuppressive Capacity of Myeloid-Derived Suppressor Cells Independent of Arginase 1
Aarstad et al. Plasma IL-1 and IL-6 family cytokines with soluble receptor levels at diagnosis in head and neck squamous cell carcinoma: high levels predict decreased five-year disease-specific and overall survival
Suksamai et al. Cyclic GMP-AMP Synthase (cGAS) Deletion Promotes Less Prominent Inflammatory Macrophages and Sepsis Severity in Catheter-Induced Infection and LPS Injection Models
Milardi et al. Molecular Remodeling of the Sperm Proteome Following Varicocele Sclero-Embolization: Implications for Semen Quality Improvement
Yabas et al. Immunological phenotyping of mice with a point mutation in Cdk4
Mathew et al. Altered Expression of NK Receptors in Racially/Ethnically Diverse and Risk-of-Relapse Pediatric Acute Lymphoblastic Leukemia Patients
Gasparini et al. Proteasome inhibitors induce apoptosis in ex vivo cells of T-cell prolymphocytic leukemia